Type 2, which affects 10% of patients, is associated with an abnormality of the NF2 gene, formerly called central neurofibromatosis or bilateral acoustic neurofibromatosis; however, this mainly affects the central nervous system, rather than the gastrointestinal tract (5). This evidence concerns the gene NF2 and neurofibromatosis.